Unraveling resistance to trastuzumab (Herceptin): Insulin-like growth factor-I receptor, a new suspect

被引：73
作者：
Albanell, J
Baselga, J
机构：
[1] Vall dHebron Univ Hosp, Med Oncol Serv, Barcelona 08035, Spain
[2] Univ Autonoma Barcelona, E-08193 Barcelona, Spain
来源：
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE | 2001年 / 93卷 / 24期
关键词：
D O I：
10.1093/jnci/93.24.1830
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1830 / 1832
页数：3
相关论文
共 30 条
[1]  
ANIDO J, 2001, P ASCO, V20, P1712
[2]   Activation of ErbB-2 via a hierarchical interaction between ErbB-2 and type I insulin-like growth factor receptor in mammary tumor cells [J].
Balañá, ME ;
Labriola, L ;
Salatino, M ;
Movsichoff, F ;
Peters, G ;
Charreau, EH ;
Elizalde, PV .
ONCOGENE, 2001, 20 (01) :34-47
[3]  
Bartucci M, 2001, CANCER RES, V61, P6747
[4]   Mechanism of action of anti-HER2 monoclonal antibodies [J].
Baselga, J ;
Albanell, J .
ANNALS OF ONCOLOGY, 2001, 12 :35-41
[5]  
Baselga J, 2001, J CLIN ONCOL, V19, p41S
[6]   Phase II study of weekly intravenous recombinant humanized Anti-p185(HER2) monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast [J].
Baselga, J ;
Tripathy, D ;
Mendelsohn, J ;
Baughman, S ;
Benz, CC ;
Dantis, L ;
Sklarin, NT ;
Seidman, AD ;
Hudis, CA ;
Moore, J ;
Rosen, PP ;
Twaddell, T ;
Henderson, IC ;
Norton, L .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (03) :737-744
[7]  
Chan TW, 2001, CLIN CANCER RES, V7, P2545
[8]   Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets [J].
Clynes, RA ;
Towers, TL ;
Presta, LG ;
Ravetch, JV .
NATURE MEDICINE, 2000, 6 (04) :443-446
[9]   Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease [J].
Cobleigh, MA ;
Vogel, CL ;
Tripathy, D ;
Robert, NJ ;
Scholl, S ;
Fehrenbacher, L ;
Wolter, JM ;
Paton, V ;
Shak, S ;
Lieberman, G ;
Slamon, DJ .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) :2639-2648
[10]   Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. [J].
Druker, BJ ;
Talpaz, M ;
Resta, DJ ;
Peng, B ;
Buchdunger, E ;
Ford, JM ;
Lydon, NB ;
Kantarjian, H ;
Capdeville, R ;
Ohno-Jones, S ;
Sawyers, CL .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1031-1037
123